复宏汉霖(02696.HK):欧盟委员会批准斯鲁利单抗注射液新增适应症:联合化疗适用于不可手术切除的局部晚期或转移性鳞状非小细胞肺癌(sqNSCLC)成人患者的一线治疗

智通财经
Jun 25
【复宏汉霖(02696.HK):欧盟委员会批准斯鲁利单抗注射液新增适应症:联合化疗适用于不可手术切除的局部晚期或转移性鳞状非小细胞肺癌(sqNSCLC)成人患者的一线治疗】智通财经APP讯,复宏汉霖(02696.HK)发布公告,近日,欧盟委员会(European Commission, EC)已批准本公司自主开发的斯鲁利单抗注射液(中国境内商品名:汉斯状®;欧盟商品名:HETRONIFLY®)( 斯鲁利单抗)新增适应症:斯鲁利单抗联合卡铂和白蛋白紫杉醇适用于不可手术切除的局部晚期或转移性鳞状非小细胞肺癌(sqNSCLC)成人患者的一线治疗(本次新增适应症)。此次获批意味着斯鲁利单抗本次新增适应症在所有欧盟成员国及冰岛、列支敦士登和挪威(各自为欧洲经济区(EEA)国家)获得批准。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10